These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38894848)

  • 1. Remdesivir is Associated with Reduced Mortality in Patients Hospitalized for COVID-19 Not Requiring Supplemental Oxygen.
    Mozaffari E; Chandak A; Chima-Melton C; Kalil AC; Jiang H; Lee E; Der-Torossian C; Thrun M; Berry M; Haubrich R; Gottlieb RL
    Open Forum Infect Dis; 2024 Jun; 11(6):ofae202. PubMed ID: 38894848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Remdesivir Is Associated With Reduced Mortality in COVID-19 Patients Requiring Supplemental Oxygen Including Invasive Mechanical Ventilation Across SARS-CoV-2 Variants.
    Mozaffari E; Chandak A; Gottlieb RL; Chima-Melton C; Read SH; Lee E; Der-Torossian C; Gupta R; Berry M; Hollemeersch S; Kalil AC
    Open Forum Infect Dis; 2023 Oct; 10(10):ofad482. PubMed ID: 37869410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Remdesivir Reduced Mortality in Immunocompromised Patients Hospitalized for COVID-19 Across Variant Waves: Findings From Routine Clinical Practice.
    Mozaffari E; Chandak A; Gottlieb RL; Chima-Melton C; Read SH; Jiang H; Chiang M; Lee E; Gupta R; Berry M; Kalil AC
    Clin Infect Dis; 2023 Dec; 77(12):1626-1634. PubMed ID: 37556727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Remdesivir Treatment in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19): A Comparative Analysis of In-hospital All-cause Mortality in a Large Multicenter Observational Cohort.
    Mozaffari E; Chandak A; Zhang Z; Liang S; Thrun M; Gottlieb RL; Kuritzkes DR; Sax PE; Wohl DA; Casciano R; Hodgkins P; Haubrich R
    Clin Infect Dis; 2022 Aug; 75(1):e450-e458. PubMed ID: 34596223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of Vulnerable Patients Hospitalized for COVID-19 With Remdesivir: A Retrospective Comparative Effectiveness Study of Mortality in US Hospitals.
    Mozaffari E; Chandak A; Berry M; Sax PE; Loubet P; Doi Y; Amin AN; Ahuja N; Müller V; Casciano R; Kolditz M
    Clin Infect Dis; 2024 Dec; 79(Supplement_4):S137-S148. PubMed ID: 39423791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lower mortality risk associated with remdesivir + dexamethasone versus dexamethasone alone for the treatment of patients hospitalized for COVID-19.
    Mozaffari E; Chandak A; Gottlieb RL; Chima-Melton C; Berry M; Oppelt T; Okulicz JF; Amin AN; Welte T; Sax PE; Kalil AC
    Clin Infect Dis; 2024 Sep; ():. PubMed ID: 39302162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Remdesivir Treatment With Survival and Length of Hospital Stay Among US Veterans Hospitalized With COVID-19.
    Ohl ME; Miller DR; Lund BC; Kobayashi T; Richardson Miell K; Beck BF; Alexander B; Crothers K; Vaughan Sarrazin MS
    JAMA Netw Open; 2021 Jul; 4(7):e2114741. PubMed ID: 34264329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Remdesivir Treatment Lacks the Effect on Mortality Reduction in Hospitalized Adult COVID-19 Patients Who Required High-Flow Supplemental Oxygen or Invasive Mechanical Ventilation.
    Huang C; Lu TL; Lin L
    Medicina (Kaunas); 2023 May; 59(6):. PubMed ID: 37374231
    [No Abstract]   [Full Text] [Related]  

  • 9. Patients with moderate to severe COVID-19 outcomes on remdesivir according to baseline 4C mortality score.
    Sellers J; Chang J; Jones J; Hintze TD
    Pulm Pharmacol Ther; 2023 Feb; 78():102188. PubMed ID: 36603741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological treatment in pregnant women with moderate symptoms of coronavirus disease 2019 (COVID-19) pneumonia.
    Nasrallah S; Nguyen AQ; Hitchings L; Wang JQ; Hamade S; Maxwell GL; Khoury A; Gomez LM
    J Matern Fetal Neonatal Med; 2022 Dec; 35(25):5970-5977. PubMed ID: 33771091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early administration of remdesivir may reduce mortality in hospitalized COVID-19 patients : A propensity score matched analysis.
    Karolyi M; Kaltenegger L; Pawelka E; Kuran A; Platzer M; Totschnig D; Koenig F; Hoepler W; Laferl H; Omid S; Seitz T; Traugott M; Arthofer S; Erlbeck L; Jaeger S; Kettenbach A; Assinger A; Wenisch C; Zoufaly A
    Wien Klin Wochenschr; 2022 Dec; 134(23-24):883-891. PubMed ID: 36301355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of patients hospitalized for COVID-19 with remdesivir is associated with lower likelihood of 30-day readmission: a retrospective observational study.
    Mozaffari E; Chandak A; Gottlieb RL; Chima-Melton C; Kalil AC; Sarda V; Der-Torossian C; Oppelt T; Berry M; Amin AN
    J Comp Eff Res; 2024 Apr; 13(4):e230131. PubMed ID: 38420658
    [No Abstract]   [Full Text] [Related]  

  • 14. Remdesivir for Treatment of COVID-19 Requiring Oxygen Support: A Cross-Study Comparison From 2 Large, Open-Label Studies.
    Fusco D; Malenica I; Günthard HF; Gupta SK; Kurbegov D; Balani B; Olender S; Aberg JA; Telep LE; Tian Y; Blair C; Wu G; Haubrich RH; Wang CY; Chokkalingam AP; Osinusi AO; Wendtner CM; Gottlieb RL
    Clin Infect Dis; 2024 Nov; 79(5):1182-1189. PubMed ID: 38920297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness Analysis and Impact on Length of Hospital Stay of the Introduction of Remdesivir as a Treatment Option for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen in Greece Versus Standard of Care.
    Athanasakis K; Zisis K; Tsoulas C; Nomikos N
    Clin Ther; 2023 Dec; 45(12):1244-1250. PubMed ID: 37914586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Remdesivir Versus Standard-of-Care for Severe Coronavirus Disease 2019 Infection: An Analysis of 28-Day Mortality.
    Olender SA; Walunas TL; Martinez E; Perez KK; Castagna A; Wang S; Kurbegov D; Goyal P; Ripamonti D; Balani B; De Rosa FG; De Wit S; Kim SW; Diaz G; Bruno R; Mullane KM; Lye DC; Gottlieb RL; Haubrich RH; Chokkalingam AP; Wu G; Diaz-Cuervo H; Brainard DM; Lee IH; Hu H; Lin L; Osinusi AO; Bernardino JI; Boffito M
    Open Forum Infect Dis; 2021 Jul; 8(7):ofab278. PubMed ID: 34282406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of Remdesivir Treatment Protocols Among Patients Hospitalized with COVID-19: A Target Trial Emulation.
    Breskin A; Wiener C; Adimora AA; Brown RS; Landis C; Reddy KR; Verna EC; Crawford JM; Mospan A; Fried MW; Brookhart MA
    Epidemiology; 2023 May; 34(3):365-375. PubMed ID: 36719738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Remdesivir versus Favipiravir in Hospitalized Patients with Moderate to Severe COVID-19 Pneumonia: A Propensity Score-Matched Retrospective Cohort Study.
    Chavalertsakul K; Sutherasan Y; Petnak T; Thammavaranucupt K; Kirdlarp S; Boonsarngsuk V; Sungkanuparph S
    Int J Gen Med; 2024; 17():2163-2175. PubMed ID: 38770366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remdesivir-Associated Survival Outcomes Among Immunocompromised Patients Hospitalized for COVID-19: Real-world Evidence From the Omicron-Dominant Era.
    Mozaffari E; Chandak A; Gottlieb RL; Chima-Melton C; Berry M; Amin AN; Sax PE; Kalil AC
    Clin Infect Dis; 2024 Dec; 79(Supplement_4):S149-S159. PubMed ID: 39405443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors for poor outcomes in patients with severe COVID-19 treated with remdesivir plus dexamethasone in Taiwan.
    Lai YH; Lee YC; Chen IR; Lin SN; Chang YL; Lu CC; Wu PF; Lin YT
    J Microbiol Immunol Infect; 2023 Dec; 56(6):1207-1213. PubMed ID: 37696685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.